On January 14, 2025, Charles River Laboratories International, Inc. presented at the 43rd Annual J.P. Morgan Healthcare Conference, sharing insights into their strategic focus, business developments, and the financial outlook for 2025. They forecast a similar decline in 2025 revenue as observed in 2024 due to various factors including restructuring in global biopharma, and stable demand from biotech clients. They also highlighted challenges in their Contract Development and Manufacturing Organiz